Mitochondrial Dysfunction in Diabetic Cardiomyopathy: The Possible Therapeutic Roles of Phenolic Acids

• Published in: International journal of molecular sciences Vol. 21; no. 17; p. 6043
• Main Authors: Jubaidi, Fatin Farhana, Zainalabidin, Satirah, Mariappan, Vanitha, Budin, Siti Balkis
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22-08-2020; MDPI
• Subjects: Acids; Adenosine Triphosphate - metabolism; Animals; Apoptosis; Apoptosis - drug effects; Apoptosis - physiology; Cardiomyocytes; Cardiomyopathy; Cardiotonic Agents - chemistry; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cardiovascular disease; Collagen; Congestive heart failure; Connective tissue; Coronary vessels; Diabetes; Diabetes mellitus; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - pathology; Fibrosis; Growth factors; Heart failure; Humans; Hydroxybenzoates - pharmacology; Hydroxybenzoates - therapeutic use; Hypertension; inflammation; Inflammation - etiology; Insulin; Insulin Resistance; Magnetic resonance imaging; Mitochondria; Mitochondria, Heart - drug effects; Mitochondria, Heart - pathology; Mitochondria, Heart - physiology; Mortality; natural products; Oxidative stress; Oxidative Stress - drug effects; Pathogenesis; Pathophysiology; Phenolic acids; Researchers; Review; natural products; apoptosis; diabetes mellitus; inflammation; oxidative stress
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21176043

As the powerhouse of the cells, mitochondria play a very important role in ensuring that cells continue to function. Mitochondrial dysfunction is one of the main factors contributing to the development of cardiomyopathy in diabetes mellitus. In early development of diabetic cardiomyopathy (DCM), patients present with myocardial fibrosis, dysfunctional remodeling and diastolic dysfunction, which later develop into systolic dysfunction and eventually heart failure. Cardiac mitochondrial dysfunction has been implicated in the development and progression of DCM. Thus, it is important to develop novel therapeutics in order to prevent the progression of DCM, especially by targeting mitochondrial dysfunction. To date, a number of studies have reported the potential of phenolic acids in exerting the cardioprotective effect by combating mitochondrial dysfunction, implicating its potential to be adopted in DCM therapies. Therefore, the aim of this review is to provide a concise overview of mitochondrial dysfunction in the development of DCM and the potential role of phenolic acids in combating cardiac mitochondrial dysfunction. Such information can be used for future development of phenolic acids as means of treating DCM by alleviating the cardiac mitochondrial dysfunction.